5 results
Primary objective:Pharmacokinetics/-dynamics of 124I-F8IL10 Secondary objective:Dosimetric parameters of arthritic joints and internal organs.
Aim of this study proposal· To establish whether oral phosphorus binding is able to reduce FGF23 levels in patients with CKD stage 3.· To evaluate if a reduction of serum phosphate and FGF23 improves vascular function as measured by pulse-wave-…
To demonstrate the feasibility to induce an effective, predictable and sustained decrease in FGF23 level in CKD stage I-IV patients, without inducing hypophosphatemia using a stepped treatment regimen aiming at restricting phosphate uptake.
There are two treatment groups in this study: one with participants at low risk of deterioration and one with participants at standard risk of deterioration. The primary objective for each group is described below.-Low Risk group: To describe the…
Primary Objective is to test the feasibility of a strategy in which patient preference, after a short exposure to treatment options, determines the choice for a specific phosphate binder and whether this strategy will improve patient*s satisfaction.…